Can You Use Synchronized Cardioversion for AFib? Yes, With Limits

Yes, synchronized cardioversion is a legitimate treatment for atrial fibrillation, but it is an elective rhythm-control procedure for selected patients, not a routine first step. It works best for AFib that started within about 48 hours to 7 days, in patients who are hemodynamically stable and adequately anticoagulated. Unstable patients need urgent electricity; stable patients need planning, because the shock itself is easy and the stroke risk is what demands care.

The word "synchronized" matters. The defibrillator reads the QRS complex and times the shock to fall with the ventricle's electrical discharge, avoiding the vulnerable T-wave period when a shock can trigger ventricular fibrillation. In AFib, the atria are chaotic but the ventricles still conduct in an organized way, so there is a signal to sync to. That is why cardioversion for AFib is synchronized cardioversion rather than the unsynchronized shock used for ventricular fibrillation (FDA).

The deeper question is not whether the shock can restore sinus rhythm. It usually can, with roughly 70% to 90% success for a first attempt in appropriately selected patients. The real question is whether restoring rhythm helps this patient more than rate control and anticoagulation alone. That answer depends on symptoms, duration, atrial size, and how long the patient has been in AFib.

Mechanism: Why Timing a Shock Works

Every heartbeat starts with an electrical wave that sweeps across the atria and then the ventricles. In AFib, the atria fire in disorganized swirls at 300 to 600 impulses per minute, and the AV node passes a random fraction of them to the ventricles. The result is an irregular pulse and loss of the atrial kick that normally adds 15% to 30% of ventricular filling.

A synchronized shock delivers a brief high-energy pulse, typically 50 to 200 joules biphasic, across the chest. The goal is to depolarize a critical mass of atrial myocardium at once so the chaotic circuits go dark. The sinus node, which sits high in the right atrium, then resumes as the pacemaker. The shock does not "reset" a broken heart so much as stun the fibrillating tissue long enough for organized conduction to return.

The synchronization circuit reads the R wave and fires 10 to 30 milliseconds after it, outside the T wave. Without that timing, a shock that lands during ventricular repolarization can induce ventricular fibrillation, a lethal arrhythmia. This is the single most important technical detail: correct synchronization, confirmed on the monitor, before pressing the button.

Cardioversion also does not fix the substrate. The pulmonary vein triggers and the fibrotic atrial remodeling that sustain AFib remain. That is why recurrence is common and why the procedure is best understood as resetting the rhythm, not curing the disease.

Quantified Context: Success, Recurrence, and Stroke Risk

Electrical cardioversion restores sinus rhythm in about 70% to 90% of patients on the first attempt, with higher success for shorter AFib duration and smaller left atria. Recurrence is the harder number. Without antiarrhythmic drugs, roughly 25% to 50% of patients are back in AFib within a month, and more than half recur within a year.

The stroke risk is the number that drives guidelines. Cardioversion of AFib lasting more than 48 hours carries a thromboembolic risk of roughly 1% to 5% without anticoagulation, because restoring atrial contraction can eject a clot that formed in the stunned atrium. The 48-hour threshold is not a law of physiology; it is a practical cutoff derived from observational data showing that clots are rare below it and rise afterward.

That is why the standard of care is anticoagulation for at least 3 weeks before and 4 weeks after cardioversion when AFib has lasted more than 48 hours. For patients who cannot wait, transesophageal echocardiography can exclude a left atrial thrombus and allow earlier cardioversion with anticoagulation continued afterward. The two strategies reconcile like this: the 3-week rule is for patients without a TEE, and the TEE route is the shortcut with its own ongoing anticoagulation requirement, typically a direct oral anticoagulant at full dose for at least 4 weeks after the shock.

Timing matters too. AFib present for less than 48 hours can often be cardioverted without prolonged pre-treatment if the patient is stable, while AFib present for weeks or months has lower success and higher recurrence. A larger left atrium, above roughly 5.5 to 6.0 cm, predicts lower success and more recurrence, though it is not an absolute barrier.

Timeline: What Happens Around a Cardioversion

The first four weeks after cardioversion are the highest-risk period for both recurrence and thromboembolism, which is why anticoagulation continues even if the ECG shows sinus rhythm. The atria can take weeks to recover mechanical contraction, so the electrical rhythm and the mechanical function do not return together. This is the counterintuitive detail many patients miss: a normal ECG does not mean the stroke risk has passed.

Edge Cases: When the Answer Changes

Hemodynamic instability changes everything. If AFib is causing hypotension, angina, pulmonary edema, or shock, urgent synchronized cardioversion is indicated without waiting for the anticoagulation window, because the immediate threat outweighs the stroke risk. This is the one scenario where the procedure is not elective.

Recent-onset AFib under 48 hours is another edge. Many clinicians will cardiovert after a risk assessment, but the "48-hour rule" assumes the onset is known with confidence. If the patient cannot reliably date the onset, treat it as longer than 48 hours and follow the anticoagulation pathway.

Pacemaker and ICD patients require attention to device programming before and after the shock. The energy can reset or damage the device, so interrogation after the procedure is standard. Patients with severe valvular disease, particularly mitral stenosis or a mechanical valve, carry higher stroke risk and often need warfarin rather than a direct oral anticoagulant.

Pregnancy, severe electrolyte disturbance, and uncontrolled thyroid disease are relative cautions. Digitalis toxicity is a specific hazard because it can make the myocardium irritable and increase the risk of post-shock ventricular arrhythmia. None of these are absolute contraindications, but they change the preparations.

Misconceptions: What Cardioversion Is Not

The most common misconception is that cardioversion cures AFib. It restores sinus rhythm temporarily, but the underlying atrial disease persists. The recurrence numbers above are the proof.

A second is that the shock is always the dangerous part. In stable patients, the shock is brief and usually well tolerated under sedation. The dangerous part is the clot, and the anticoagulation plan is the real safety measure.

A third is that a successful cardioversion means anticoagulation can stop. Guidelines from the American Heart Association and American College of Cardiology tie anticoagulation to stroke risk scores, not to rhythm. A patient with a high CHA2DS2-VASc score remains on anticoagulation even in sinus rhythm, because episodes of silent AFib can recur.

A fourth is that cardioversion and catheter ablation are the same thing. Cardioversion is a shock to reset rhythm. Ablation destroys the tissue that triggers AFib, usually around the pulmonary veins, and is a separate procedure with its own indications.

Red flag: shock delivered without confirmed synchronization can cause ventricular fibrillation. Red flag: cardioversion of AFib over 48 hours without anticoagulation or TEE risks stroke. Red flag: a hypotensive, ischemic, or pulmonary-edema patient needs urgent cardioversion, not a clinic appointment. Red flag: a suspected left atrial thrombus on TEE cancels elective cardioversion until treated.

Practical Actions: A Concrete Pathway

Step one: confirm the diagnosis. An ECG showing irregularly irregular rhythm without P waves is the baseline. The onset date is the most important history item you can collect.

Step two: assess stability. Blood pressure, chest pain, mental status, and signs of pulmonary edema decide urgent versus elective.

Step three: check stroke risk. A CHA2DS2-VASc score of 2 or more in men, or 3 or more in women, generally means anticoagulation regardless of rhythm outcome. This is a guideline-based threshold, not a personalized prescription.

Step four: plan the anticoagulation window. AFib over 48 hours means at least 3 weeks of full-dose anticoagulation before the shock, or a TEE to exclude thrombus, then at least 4 weeks afterward.

Step five: prepare the procedure. Correct pad placement, confirmed synchronization on the monitor, sedation with airway support available, and a post-shock rhythm check.

Step six: arrange follow-up. An ECG at 4 to 6 weeks, symptom review, and a decision about antiarrhythmic therapy if AFib recurs.

Comparison: Cardioversion Versus Alternatives

The table makes the tradeoff clear. Cardioversion is the fastest route to sinus rhythm, but it is a rhythm reset, not a durable fix. Ablation has higher long-term success but is invasive. Rate control and anticoagulation remain the backbone for many patients, especially those with few symptoms.

Limitations: Where the Evidence Is Thin

The evidence base for cardioversion is strong on procedural success and stroke prevention, but weaker on hard outcomes. Trials comparing rhythm control with rate control have generally shown similar mortality, which is why cardioversion is offered for symptom relief rather than longevity.

The 48-hour threshold is a pragmatic cutoff, not a precisely validated biological boundary. Some patients with AFib under 48 hours still have thrombus, and some with longer duration do not. The TEE strategy exists precisely because the rule is imperfect.

Anticoagulation decisions after successful cardioversion remain individualized. The guidelines give thresholds, but bleeding risk, kidney function, and patient preference all enter the calculation. This is where a cardiologist's judgment matters more than any single number.

Finally, the procedure itself has small but real risks: sedation complications, skin burns, and rare post-shock bradycardia requiring pacing. These are uncommon, but they are why cardioversion is done in a monitored setting with resuscitation equipment available.

The short answer stands. Synchronized cardioversion is a valid, effective option for AFib in the right patient with the right preparation. The long answer is that the shock is the easy part; the anticoagulation plan, the onset history, and the recurrence conversation are what determine whether it helps.